• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

ETV4在人类肿瘤中的致癌作用及药物敏感性：一项泛癌分析。

Oncogenic role and drug sensitivity of ETV4 in human tumors: a pan-cancer analysis.

作者信息

Zhang Rui, Peng Yanfang, Gao Zhe, Qian Jing, Yang Kang, Wang Xinfa, Lu Wenjing, Zhu Yongjie, Qiu Dezhi, Jin Tong, Wang Gang, He Junping, Liu Ning

机构信息

Department of Neurosurgery, Children's Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.

Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.

出版信息

Front Oncol. 2023 May 2;13:1121258. doi: 10.3389/fonc.2023.1121258. eCollection 2023.

DOI:10.3389/fonc.2023.1121258
PMID:37205199
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10185867/
Abstract

BACKGROUND

Increasing evidence supports a relationship between E twenty-six variant transcription factor 4 (ETV4) and several cancers, but no pan-cancer analysis has been reported.

METHODS

The present study surveyed the effects of ETV4 on cancer using RNA sequencing data obtained from The Cancer Genome Atlas and GTEx, and further explored its role in drug sensitivity using data from Cellminer. Differential expression analyses were conducted for multiple cancers using R software. Cox regression and survival analysis were employed to calculate correlations between ETV4 levels and survival outcomes in multiple cancers using the online tool Sangerbox. ETV4 expression was also compared with immunity, heterogeneity, stemness, mismatch repair genes, and DNA methylation among different cancers.

RESULTS

ETV4 was found to be significantly upregulated in 28 tumors. Upregulation of ETV4 was associated with poor overall survival, progression free interval, disease-free-interval, and disease specific survival in several cancer types. Expression of ETV4 was also remarkably correlated with immune cell infiltration, tumor heterogeneity, mismatch repair gene expression, DNA methylation, and tumor stemness. Furthermore, ETV4 expression seemed to affect sensitivity to a number of anticancer drugs.

CONCLUSIONS

These results suggest that ETV4 may be useful as a prognostic factor and therapeutic target.

摘要

背景

越来越多的证据支持E26变异转录因子4（ETV4）与多种癌症之间存在关联，但尚未见泛癌分析报道。

方法

本研究利用从癌症基因组图谱（The Cancer Genome Atlas，TCGA）和基因型-组织表达（Genotype-Tissue Expression，GTEx）数据库获得的RNA测序数据，研究ETV4对癌症的影响，并利用Cellminer数据库的数据进一步探索其在药物敏感性方面的作用。使用R软件对多种癌症进行差异表达分析。使用在线工具Sangerbox通过Cox回归和生存分析计算ETV4水平与多种癌症生存结果之间的相关性。还比较了不同癌症中ETV4表达与免疫、异质性、干性、错配修复基因和DNA甲基化的关系。

结果

发现ETV4在28种肿瘤中显著上调。在几种癌症类型中，ETV4的上调与总体生存率低、无进展生存期短、无病生存期短和疾病特异性生存期短相关。ETV4的表达还与免疫细胞浸润、肿瘤异质性、错配修复基因表达、DNA甲基化和肿瘤干性显著相关。此外，ETV4的表达似乎影响对多种抗癌药物的敏感性。

结论

这些结果表明，ETV4可能作为一种预后因素和治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5c7/10185867/32f9f05684aa/fonc-13-1121258-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5c7/10185867/b90b1942d29e/fonc-13-1121258-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5c7/10185867/38e8f2b48201/fonc-13-1121258-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5c7/10185867/b612d8c3bf41/fonc-13-1121258-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5c7/10185867/35712a9b7ff4/fonc-13-1121258-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5c7/10185867/6870a99cbbf7/fonc-13-1121258-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5c7/10185867/eea829d005fc/fonc-13-1121258-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5c7/10185867/408c93260af3/fonc-13-1121258-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5c7/10185867/c4d52537017e/fonc-13-1121258-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5c7/10185867/32f9f05684aa/fonc-13-1121258-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5c7/10185867/b90b1942d29e/fonc-13-1121258-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5c7/10185867/38e8f2b48201/fonc-13-1121258-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5c7/10185867/b612d8c3bf41/fonc-13-1121258-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5c7/10185867/35712a9b7ff4/fonc-13-1121258-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5c7/10185867/6870a99cbbf7/fonc-13-1121258-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5c7/10185867/eea829d005fc/fonc-13-1121258-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5c7/10185867/408c93260af3/fonc-13-1121258-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5c7/10185867/c4d52537017e/fonc-13-1121258-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5c7/10185867/32f9f05684aa/fonc-13-1121258-g009.jpg

相似文献

1
Oncogenic role and drug sensitivity of ETV4 in human tumors: a pan-cancer analysis.ETV4在人类肿瘤中的致癌作用及药物敏感性：一项泛癌分析。
Front Oncol. 2023 May 2;13:1121258. doi: 10.3389/fonc.2023.1121258. eCollection 2023.
2
Comprehensive Analysis Reveals USP45 as a Novel Putative Oncogene in Pan-Cancer.综合分析揭示USP45是一种泛癌中新的假定癌基因。
Front Mol Biosci. 2022 Jun 28;9:886904. doi: 10.3389/fmolb.2022.886904. eCollection 2022.
3
Comprehensive Pan-Cancer Analysis of KIF18A as a Marker for Prognosis and Immunity.全面泛癌分析 KIF18A 作为预后和免疫标志物。
Biomolecules. 2023 Feb 8;13(2):326. doi: 10.3390/biom13020326.
4
A systemic pan-cancer analysis of MPZL3 as a potential prognostic biomarker and its correlation with immune infiltration and drug sensitivity in breast cancer.MPZL3作为一种潜在的预后生物标志物的全癌系统分析及其与乳腺癌免疫浸润和药物敏感性的相关性
Front Oncol. 2022 Jul 29;12:901728. doi: 10.3389/fonc.2022.901728. eCollection 2022.
5
A comprehensive analysis and validation of cuproptosis-associated genes across cancers: Overall survival, the tumor microenvironment, stemness scores, and drug sensitivity.跨癌症的铜死亡相关基因的综合分析与验证：总生存期、肿瘤微环境、干性评分和药物敏感性。
Front Genet. 2022 Aug 29;13:939956. doi: 10.3389/fgene.2022.939956. eCollection 2022.
6
Ferredoxin 1 is a cuproptosis-key gene responsible for tumor immunity and drug sensitivity: A pan-cancer analysis.铁氧还蛋白1是一种与铜死亡相关的关键基因，负责肿瘤免疫和药物敏感性：一项泛癌分析。
Front Pharmacol. 2022 Sep 21;13:938134. doi: 10.3389/fphar.2022.938134. eCollection 2022.
7
Integrative Pan-Cancer Analysis Confirmed that FCGR3A is a Candidate Biomarker Associated With Tumor Immunity.综合泛癌分析证实FCGR3A是一种与肿瘤免疫相关的候选生物标志物。
Front Pharmacol. 2022 May 20;13:900699. doi: 10.3389/fphar.2022.900699. eCollection 2022.
8
Pan-cancer analysis of the prognostic and immunological roles of () in human tumors.（）在人类肿瘤中的预后及免疫作用的泛癌分析。 （注：原文括号处内容缺失）
Front Genet. 2022 Oct 13;13:1039440. doi: 10.3389/fgene.2022.1039440. eCollection 2022.
9
Prognostic Implication and Oncogenic Role of PNPO in Pan-Cancer.PNPO在泛癌中的预后意义及致癌作用
Front Cell Dev Biol. 2022 Jan 21;9:763674. doi: 10.3389/fcell.2021.763674. eCollection 2021.
10
Pan-cancer analysis of trophinin-associated protein with potential implications in clinical significance, prognosis, and tumor microenvironment in human cancers.滋养素相关蛋白的泛癌分析及其在人类癌症临床意义、预后和肿瘤微环境中的潜在影响
Front Oncol. 2022 Nov 7;12:971618. doi: 10.3389/fonc.2022.971618. eCollection 2022.

引用本文的文献

1
Identification of ETV4 as a prognostic biomarker and correlates with immune cell infiltration in head and neck squamous cell carcinoma.鉴定ETV4作为头颈部鳞状细胞癌的预后生物标志物及其与免疫细胞浸润的相关性。
Sci Rep. 2025 Feb 27;15(1):7044. doi: 10.1038/s41598-025-90731-8.
2
Model ensembling as a tool to form interpretable multi-omic predictors of cancer pharmacosensitivity.模型集成作为一种工具，用于构建癌症药物敏感性的可解释多组学预测因子。
Brief Bioinform. 2024 Sep 23;25(6). doi: 10.1093/bib/bbae567.
3
GALNT5 functions as a suppressor of ferroptosis and a predictor of poor prognosis in pancreatic adenocarcinoma.

本文引用的文献

1
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth.不断演变的肿瘤微环境：从癌症起始到转移灶生长
Cancer Cell. 2023 Mar 13;41(3):374-403. doi: 10.1016/j.ccell.2023.02.016.
2
Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment.错配修复缺陷/微卫星不稳定结直肠肿瘤：诊断、预后和治疗。
Eur J Cancer. 2022 Nov;175:136-157. doi: 10.1016/j.ejca.2022.07.020. Epub 2022 Sep 14.
3
GLOBOCAN 2020 Report on Global Cancer Burden: Challenges and Opportunities for Surgical Oncologists.
GALNT5作为一种铁死亡抑制因子及胰腺腺癌预后不良的预测指标发挥作用。
Am J Cancer Res. 2023 Oct 15;13(10):4579-4596. eCollection 2023.
GLOBOCAN 2020 全球癌症负担报告：外科肿瘤学家面临的挑战和机遇。
Ann Surg Oncol. 2022 Oct;29(11):6497-6500. doi: 10.1245/s10434-022-12151-6. Epub 2022 Jul 15.
4
The role of DNA mismatch repair in immunotherapy of human cancer.DNA 错配修复在人类癌症免疫治疗中的作用。
Int J Biol Sci. 2022 Apr 4;18(7):2821-2832. doi: 10.7150/ijbs.71714. eCollection 2022.
5
ETS factors in prostate cancer.ETS 因素与前列腺癌。
Cancer Lett. 2022 Apr 1;530:181-189. doi: 10.1016/j.canlet.2022.01.009. Epub 2022 Jan 14.
6
E26 transformation-specific variant 4 as a tumor promotor in human cancers through specific molecular mechanisms.E26转化特异性变体4通过特定分子机制在人类癌症中作为肿瘤促进因子。
Mol Ther Oncolytics. 2021 Jul 29;22:518-527. doi: 10.1016/j.omto.2021.07.012. eCollection 2021 Sep 24.
7
Tumor heterogeneity.肿瘤异质性。
Cancer Cell. 2021 Aug 9;39(8):1015-1017. doi: 10.1016/j.ccell.2021.07.009.
8
ETV4 promotes breast cancer cell stemness by activating glycolysis and CXCR4-mediated sonic Hedgehog signaling.ETV4通过激活糖酵解和CXCR4介导的音猬因子信号通路促进乳腺癌细胞干性。
Cell Death Discov. 2021 May 29;7(1):126. doi: 10.1038/s41420-021-00508-x.
9
ETV4 plays a role on the primary events during the adenoma-adenocarcinoma progression in colorectal cancer.ETV4 在结直肠癌的腺瘤-腺癌进展过程中的早期事件中发挥作用。
BMC Cancer. 2021 Mar 1;21(1):207. doi: 10.1186/s12885-021-07857-x.
10
Intratumoral heterogeneity in cancer progression and response to immunotherapy.肿瘤进展和免疫治疗反应中的肿瘤内异质性。
Nat Med. 2021 Feb;27(2):212-224. doi: 10.1038/s41591-021-01233-9. Epub 2021 Feb 11.